Please use this identifier to cite or link to this item:
Title: Vaptans and hyponatremia in critical patients
Authors: D’Auria, David
Zito Marinosci, Geremia
De Benedictis, Giuseppe
Piazza, Ornella
Keywords: AVP receptor antagonists
Issue Date: 2012
Citation: D'Auria D, Zito Marinosci G, De Benedictis G, Piazza O. Vaptans and hyponatremia in critical patients. Translational Medicine @ UniSa 2012;3(1):1-14
Abstract: Hyponatremia is the most frequent fluid and electrolyte disorder in hospitalized patients (20%), particularly in ICU, associated with an increase in morbility and mortality. While hypovolaemic hyponatremia needs to be corrected with the replacement of the lost extracellular fluid by isotonic saline, euvolaemic (SIADH) and hypervolaemic hyponatremia (oedematous states like decompensated heart failure, liver cirrhosis, i.e.) are treated by restriction of fluid intake, loop diuretics and hypertonic saline. A novel approach consists in use of vaptans, non-peptide arginine vasopressin (AVP) receptor antagonists. Vaptans cause “aquaresis”, which results in the correction of plasma osmolality and serum sodium levels, without activation of the renin-angiotensin-aldosterone system or changes in blood pressure and renal function. In this paper we critically reviewed the results of the available randomized controlled critical trials, discussing the effectiveness and safety of vaptans in treating hypervolaemic and euvolaemic hyponatremia in critical patients.
ISSN: 2239-9747
Appears in Collections:Translational Medicine @ UniSa. Vol.3 (may.-aug. 2012)

Files in This Item:
File Description SizeFormat 
D. D'Auria, G. Zito Marinosci, G. De Benedictis, O. Piazza VAPTANS AND HYPONATREMIA IN CRITICAL PATIENTS (1-14).pdfarticolo di rivista475,78 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.